U.S. markets open in 2 hours 45 minutes

Orphazyme A/S (ORPH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.0700-0.1200 (-5.48%)
At close: 04:00PM EST
1.9700 -0.10 (-4.83%)
Pre-Market: 06:39AM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.1900
Bid0.0000 x 1800
Ask0.0000 x 900
Day's Range2.0550 - 2.1600
52 Week Range2.0550 - 77.7700
Avg. Volume892,832
Market Cap75.988M
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-3.8820
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ORPH

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Orphazyme A/S
    Analyst Report: Meta Platforms Inc.Meta Platforms Inc. operates the world's largest family of social networking websites, including the flagship Facebook site, Instagram, Facebook Messenger, and WhatsApp. The sites enable users to communicate with friends and family by posting to the site; commenting on others' posts; sharing photographs, website links, and videos; messaging and playing games. Meta also partners with application developers to add functionality to the sites, and allows users to pay for virtual goods and services through its Payments function. Facebook derives about 55% of its revenue from outside the U.S. and Canada. Facebook went public on May 18, 2012.
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • GlobeNewswire

    Orphazyme updates 2021 financial outlook

    Orphazyme A/SCompany announcementNo. 01/2022Inside information Company Registration No. 32266355 Net revenue range narrowed to DKK 35 – 37 millionOperating expenses lowered to DKK 665 – 675 million, due to strict cost managementCash position as of December 31, 2021, now anticipated to be no less than DKK 100 million Copenhagen – January 18, 2022 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces an update to its financial outlook for 2021 b

  • GlobeNewswire

    Orphazyme announces changes to the Board of Directors

    Orphazyme A/SCompany announcementNo. 27/2021Company Registration No. 32266355 Copenhagen – December 9, 2021 – Orphazyme A/S (ORPHA.CO; ORPH or the “Company”), a late-stage biopharmaceutical company, today announces changes to the Board of Directors, following Catherine Moukheibir’s decision to step down from her position as of December 9, 2021. Orphazyme has appointed Andrew Mercieca as Observer and Consultant to the Board of Directors with the intention that he will be proposed as a member of t

  • Zacks

    All You Need to Know About Orphazyme AS Sponsored ADR (ORPH) Rating Upgrade to Buy

    Orphazyme AS Sponsored ADR (ORPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.